Publications and conferences
• Banales J, Marin J, Lamarca A, Rodrigues P, Khan SA, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Rev Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1038/s41575-020-0310-z.• Pericleous M and Khan SA. Epidemiology of HPB Malignancy in the Elderly. EJSO 2020; (in press)
• Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD and Khan SA. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020. 72(1):95-103. doi: 10.1016/j.jhep.2019.09.007.• Dumenci OE, Abellona MR U, Khan SA, Holmes E, Taylor-Robinson SD. Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. J Hepat Carcinoma 2020; 7: 1-9.• Yousaf A, Kim J, Eliahoo J, Taylor-Robinson SD and Khan SA. Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis. J Clin Exp Hepatology 2019; J Clin Exp Hepatol. 2019 Nov-Dec;9(6):740-748. doi: 10.1016/j.jceh.2019.08.001. Epub 2019 Aug 19.PMID: 31889756• Khan SA, Genus T, Morement H, Murphy A, Rous B, Tataru B. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma – Letter to the Editor. J Hepatology 2019; 71:1261-1262• Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and Risk Factors. Liver Int 2019. DOI 10.1111/liv.14095• Wadsworth CA, Dixon PH, Taylor-Robinson SD, Kim JU, Zabron AA, Wong JH, Chapman MH, McKay SC, Spalding DR, Wasan HS, Pereira SP, Thomas HC, Whittaker JC, Williamson C and Khan SA. Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a risk factor for Cholangiocarcinoma. J Clin Exp Hep 2019;9(2):171-175. doi: 10.1016/j.jceh.2018.06.521.• Mukherjee SK, Toledano MB, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PloS One 2019;14(4):e0212779. doi: 10.1371• Howell J, Atkinson SR, 1, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019; 116: 56-66.• Appleby RN, Moghul I, Khan SA, Yee M, Manousou P, Dew T, Walters JRF. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: a prospective observational study. PloS One 2019; 25;14(1):e0211348. doi: 10.1371/journal.pone.0211348• Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nature Rev Clin Oncol 2018 15(2):95-111. doi: 10.1038/nrclinonc.2017.157..• Shabeer LL and Khan SA. Medical Students' Perception of Undergraduate Hepatology Teaching In The UK - A National Survey. Annual General Meeting of the British-Society-of-Gastroenterology. Gut 2018. BMJ Publishing Group. 67: A278-A278 (Conference Abstract).• Khan SA, McClements S, Reccia I, Evans J, Pai M and Sharma R. The Next Generation of Hepatocellular Cancer Experts – What do they think? Hepatic Onc 2017: 3(4), 213–215.• Carruthers J, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP: Nationwide trends in non-alcoholic steatohepatitis in patients with and without diabetes between 2004 and 2014 in England. Diab Res Clin Prac 2017; 132:102-107.• Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan SA, Fowell A, McPherson S, Newsome PN, Oben J, Jeremy Tomlinson J, Tsochatzis E. Frontline Gastroenterology 2017;8:252–259.• Liu NJ, Chapman R, Lin Y, Bentham A, Tyreman M, Philips N, Khan SA, Molly M. Stevens. Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. Nanoscale 2016; 8(23):11834-9.• Howell J, Khan SA, Knapp S, Thursz MR, Sharma R. The clinical role of circulating free tumour DNA in gastrointestinal malignancy. Transl Res. 2016; pii: S1931-5244(16)30461-3.• Howell J, Khan SA. The Role of miRNAs in Cholangiocarcinoma. Hepat Oncol 2016: 3(2):167-180.• Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T. ESMO Clinical Practice Guidelines On behalf of the ESMO Guidelines Working Group: Buliary Tract Cancer. Ann Oncol. 2016;27(s5):v28-v37.• International Webinar on the Management of Hepatocellular Carcinoma for Bayer in the COVID Era (2020)• British Society of Gastroenterology Committee for update of the UK guidelines on the Management of Cholangiocarcinoma (2020)• Plenary Lecture at BASL: What’s New in Cholangiocarcinoma (2019)
...
Patient reviews
K M. Verified Patient
03/02/2024
Would you recommend this doctor?
Patients comments
Very thorough testing and explanation. Thank you.
S S. Verified Patient
01/02/2024
Would you recommend this doctor?
Patients comments
Very good
M B. Verified Patient
22/12/2023
Would you recommend this doctor?
R S. Verified Patient
20/11/2023
Would you recommend this doctor?
Patients comments
Recently had consultations, tests and an endoscopy done by Prof Khan and I have to say, I was thoroughly impressed. He ensured I felt comfortable and informed throughout the process, answering all my questions and concerns. I would definitely recommend his services.